Addition of the QW Modifier to Healthcare Common Procedure Coding System (HCPCS) Codes 87811 and 87428

MLN Matters Number: MM12093
Related Change Request (CR) Number: 12093
Related CR Release Date: December 23, 2020
Effective Date: October 6, 2020
Related CR Transmittal Number: R10529OTN
Implementation Date: April 5, 2021

PROVIDER TYPES AFFECTED

This MLN Matters Article is for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

PROVIDER ACTION NEEDED

This article informs you of the addition of the QW modifier to the following CMS HCPCS codes:

- 87811 [Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])] and code
- 87428 [Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B].

Make sure your billing staffs are aware of these changes.

BACKGROUND

The Clinical Laboratory Improvement Amendments (CLIA) regulations require a facility to be appropriately certified for each test performed. To ensure that Medicare & Medicaid only pay for laboratory tests performed in certified facilities, each claim for a HCPCS code that is considered a CLIA laboratory test is currently edited at the CLIA certificate level.

We discussed HCPCS code 87811 in MLN Matters article MM12080 with an effective date of October 6, 2020. We discussed HCPCS code 87428 in the same article with an effective date of November 10, 2020.

On February 4, 2020, the HHS Secretary determined that there is a public health emergency
that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. During public health emergencies declared under Section 564 of the Federal Food, Drug, and Cosmetic (FD&C) Act, the FDA is able to issue Emergency Use Authorizations (EUAs) when certain criteria are met that allows for the use and distribution of potentially life-saving medical products to diagnose, treat, or prevent the disease, which can include diagnostic tests. Currently, there is no FDA-approved or cleared test to diagnose or detect COVID-19. The FDA has issued several In Vitro Diagnostic EUAs for SAR-CoV-2 and COVID-19.

The FDA doesn’t categorize tests authorized under an EUA. The settings in which an EUA-authorized test may be used are described in the Letter of Authorization. As discussed in the Guidance for Industry and Other Stakeholders: Emergency Use Authorization of Medical Products and Related Authorities, when the FDA authorizes tests for use at the point of care (including SARS-CoV-2 point of care test systems) under an EUA, such tests are deemed to be CLIA waived tests. For the duration of the emergency declaration, you can perform such tests in a patient care setting that is qualified to have the test performed there as a result of operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

The tests listed on the FDA’s In Vitro Diagnostic EUAs website authorized by the FDA for use at point of care under an EUA can be used by facilities having a current CLIA certificate of waiver. To be recognized as a test that can be performed in a facility having a CLIA certificate of waiver, the modifier QW must be added.

As of December 2, 2020, the FDA issued 2 individual EUAs for antigen detection by immunoassay with direct optical (that is, visual) observation for SARS-CoV-2 that are authorized for use at the Point of Care setting, that is, in patient care settings operating under a CLIA Certificate of Waiver. The HCPCS code 87811QW describes the testing performed by these 2 EUA antigen detection by immunoassay with direct optical observation SARS-CoV-2 tests.

The FDA issued one individual EUA for infectious agent antigen detection by immunoassay technique, qualitative or semiquantitative for SARS-CoV-2 and influenza virus types A and B that is authorized for use at the POC setting. The HCPCS code 87428QW describes this EUA test.

CLIA regulations require a facility to be appropriately certified for each test performed. To ensure that Medicare and Medicaid only pay for laboratory tests in a facility with a valid, current CLIA certificate, laboratory claims are currently edited at the CLIA certificate level.

- The use of code 87811QW for claims submitted by facilities with a valid, current CLIA certificate of waiver is permitted with dates of service on or after October 6, 2020.
- The use of code 87428QW for claims submitted by facilities with a valid, current CLIA certificate of waiver is permitted with dates of service on or after November 10, 2020.

MACs won’t search their files to either retract payment for claims already paid or to retroactively pay claims. However, your MAC will adjust claims that you bring to their attention.
ADDITIONAL INFORMATION

The official instruction, CR 12093, issued to your MAC regarding this change is available at https://www.cms.gov/files/document/R10529OTN.pdf.

If you have questions, your MACs may have more information. Find their website at http://go.cms.gov/MAC-website-list.

DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 23, 2020</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2019 American Medical Association. All rights reserved.

Copyright © 2013-2020, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.